J&J, Boston Scientific on Hot Seat as Panel Meeting Begins
A crucial meeting of CDRH's Circulatory System Devices Panel is underway, and already representatives from stent companies Johnson & Johnson and Boston Scientific are under fire, reports the Associated Press. The two-day meeting is expected to help FDA and doctors come to a consensus about whether the clotting risks posed by drug-eluting stents outweigh their benefits. Industry says they do not.
Whether the panel believes that will go a long way toward deciding the lucrative products' future commercialÂ prospects in the United States.